Kornimate/medical-research-clean huggingface dataset:
diagnostic performance of two tools

Conditions: Acute Kidney Injury

Summary: developing new tools for early detection of aki in open-heart surgeries.


Eligibility criteria:
inclusion criteria: * patients undergoing on-pump coronary artery bypass graft (cabg) surgery of both sexes exclusion criteria: * age less than 18 years old and more than 80 years old. patients with (ckd), chronic liver disease, heart failure, and not on diuretics or other medications that may affect renal function.
gastrointestinal evaluation in young men with iron deficiency anemia

Conditions: Anemia, Iron-Deficiency

Summary: both upper gastrointestinal endoscopy and colonoscopy are recommended in men and post-menopausal women with iron deficiency anemia. due to lack of data on the yield of these endoscopies in young men, they are currently investigated as older men. the aim of this study is to evaluate prospectively the prevalence of various gastrointestinal lesions in young men with iron deficiency anemia. our hypothesis is that the diagnostic yield of colonoscopy in young anemic men without gastrointestinal symptoms is very low, especially if a potential lesion is detected during upper gastrointestinal endoscopy. therefore, this study will try to identify predicting factors regarding the yield of both endoscopies. another purpose is to evaluate the outcome of patients with negative endoscopic results, during a follow-up of two years.


Eligibility criteria:
inclusion criteria: * men \< 40 years old of age with iron deficiency. * hemoglobin level less than 13 gr/dl documented during the 2 years prior to entering the study with one of the following: 1) iron level less than 45 μg /dl and transferrin saturation less than 10%; 2) ferritin level less than 20 μg/l (both documented during the 4 months prior to entering the study). exclusion criteria: * previously diagnosed disease that explain iron deficiency anemia * colonoscopy performed during the last 4 years * upper gastrointestinal endoscopy performed during the last 2 years

Keywords: anemia, iron-deficiency endoscopy, gastrointestinal male, aged 18 to 40
the effect of pain neuroscience education on patients with arthroscopic rotator cuff repair

Conditions: Rotator Cuff Injuries; Kinesiophobia; Pain, Postoperative

Summary: during the rehabilitation process after rotator cuff repair surgery, patients suffer from increased pain and discomfort due to dysfunction. pain neuroscience education, a more modern educational method, has been reported to be effective in controlling pain by reducing the fear of movement based on an understanding of neurophysiology.


Eligibility criteria:
inclusion criteria: * adults over 18 years old * in case of 4 weeks after receiving arthroscopic rotator cuff repair * if you wish to participate in research exclusion criteria: * 65 years old or older * those who are limited in conducting education remotely * if the tear area is large and augmentation is performed * if there is a previous surgical history at the surgical site * osteoarthritis in the shoulder joint * if you cannot understand the guidelines for evaluation or intervention * mental health and cognitive problems
modified trabeculectomy with an esst versus conventional sst for management of primary open angle glaucoma

Conditions: Primary Open-angle Glaucoma

Summary: * to evaluate prospectively the surgical outcome in terms of intraocular pressure control, potential advantages, disadvantages, success rate, complications and bleb morphology of this modified trabeculectomy with an extended subscleral tunnel (esst) in comparison to the conventional subscleral trabeculectomy (sst) in management of uncontrolled primary open angle glaucoma. * this study will recruit 40 eyes of (40) candidate patients with primary open angle glaucoma (poag) who are indicated for surgery. * the candidate patients will be recruited into 2 equal comparative groups. in group (a) 20 eyes (20 patients) who will undergo conventional (sst) with intraoperative mitomycin c (mmc) (0.03%) and group (b); 20 eyes of 20 patients will undergo trabeculectomy with an esst also with intraoperative adjunctive mmc (0.03%).

* different surgical procedures were developed and the principle behind them was to establish a fistula between the anterior chamber and the subconjunctival space to permit the aqueous humour to exit the eye. * subscleral trabeculectomy has remained the most commonly performed glaucoma surgery to which the newer operations are compared.although this procedure is very effective in reducing intraocular pressure (iop) immediately, surgical failure has often been observed over time due to fibrosis of the surgical site and resultant non-filtering bleb. -improvement of the complication profile and the efficacy of glaucoma filtering surgery is still a major concern for glaucoma surgeons.therefore, several modifications, combinations, and new techniques of subscleral trabeculectomy have been described. * in the current study, a fornix-based conjunctival flap will be fashioned in an attempt to encourage more posterior drainage. in this modified trabeculectomy technique, an additional small perpendicular strip of sclera is removed extending from the ac to 2 mm beyond the edge of the scleral flap thus creating an extended subscleral trabeculectomy facilitating aqueous passage into the posterior subconjunctival space.

Eligibility criteria:
inclusion criteria: * patients with poag aged from (40- 70) years who are candidate for glaucoma surgery with bcva ≥ 3/60 to be able to perform visual field testing. * non- compliant patients to the medical treatment willing for follow-up visits for at least 6 months post-operatively . exclusion criteria: * congenital, traumatic, neovascular, uveitic glaucomas or cases with angle closure glaucoma (acg) associated with shallow ac. * undergoing simultaneous cataract surgery. * previous vitreo-retinal surgery including vitrectomy and buckling surgery. * other pre-existing ocular cicatrizing diseases. * corneal abnormality that precluded reliable applanation tonometry.

Keywords: subscleral trabeculectomy extended subscleral tunnel mitomycinc
folic acid salt study (fisfa zambia)

Conditions: Folate Deficiency; Neural Tube Defects

Summary: question: how effective is fortified iodized salt with folic acid (fisfa) in increasing serum and red blood cell folate in non-lactating, non-pregnant women of reproductive age in the country of zambia who do not have active food fortification with a folic acid program? participants will: * consume salt with folic acid instead of their regular salt for 6 months * have a blood draw 4 times * fill out surveys

the objective of this nonrandomized controlled intervention trial is to measure the effectiveness of fortified iodized salt with folic acid (fisfa) on increasing blood folate concentrations as a preventive measure against folate-sensitive neural tube defects (ntds) in a non-fortifying country of zambia. the main questions it aims to answer are: aim 1: measure the effectiveness of fisfa on increasing serum and red blood cell folate concentrations in women of reproductive age in a non-fortifying country. aim 2: assess the risk of neural tube defects by measuring folate insufficiency levels via serum and red blood cell concentrations in women of reproductive age in a non-fortifying country. aim 3: assess taste and color acceptability of fisfa by study population.

Eligibility criteria:
inclusion criteria: * voluntary participation in the study * do not intend to get pregnant * not lactating or pregnant * live alone or with a partner if they can be compliant and not share the study salt. * aged between 18 and 45 years exclusion criteria: * pregnant or lactating

Keywords: folic acid iodine salt serum folate red blood cell folate prevention folate insufficiency malnutrition nervous system malformations spinal dysraphism vitamin b9 micronutrients
effects of an act-based psychological treatment in patients with chronic kidney disease

Conditions: Chronic Kidney Diseases; Depression

Summary: investigation of the efficacy of acceptance and commitment therapy (act) for the psychological treatment of patients with chronic kidney disease.

after being informed about the study, all patients giving written informed consent will be assessed to determine eligibility for study entry. the clinical trial will include a control group (waiting list). patients who meet eligibility requirements will be assigned to control group or intervention group. psychological intervention will consist in an 8-session individual face-to-face delivered act-based treatment. the participants will be assessed through self-report instruments before and after treatment and at 3 months follow-up.

Eligibility criteria:
inclusion criteria: * patients with chronic kidney disease on haemodialysis * older than 18 years-old * at least 3 months on haemodialysis * hads global scale score ≥14 exclusion criteria: * diagnosis of severe or chronic mental disorder, mental retardation and cognitive impairment, or disabling illness. * antidepressant drugs consume * insufficient understanding of spanish. * patients who are in the advanced chronic kidney disease unit * receiving other psychological treatment
venting effects on speech performance

Conditions: Hearing Loss

Summary: this study aims to gather behavioral data on the effect of earmold venting on speech performance in noise with a new noise reduction feature.


Eligibility criteria:
subjects fulfilling all of the following inclusion criteria are eligible for the investigation: * 18-85 years of age * experienced hearing aid users * n3-n4 hearing loss * fluent in english; ability to read and write in english * able to complete complex tasks * willing and able to provide informed consent * available for the data collection period the presence of any one of the following exclusion criteria will lead to the exclusion of the subject: * self-reported active ear-related pathology (otorrhea, dizziness, sudden hearing loss or worsening of hearing, otalgia) * visible deformity of the ear * chronic, severe tinnitus * unilateral hearing loss * cognitive impairment
the effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: in this study we evaluate the effect of pirfenidone on cough and quality of life in patients with idiopathic pulmonary fibrosis (ipf) that are treated with pirfenidone in daily practice. the hypothesis is that pirfenidone will decrease cough and increase quality of life.

rationale: idiopathic pulmonary fibrosis (ipf) is a progressive fibrotic lung disease of unknown cause with a median survival of 3-5 years. no curative treatment exists, though in 2011 pirfenidone was approved for the treatment of ipf as it appeared to slow down the decline in lung function. in patients with ipf, the most common symptoms are cough and breathlessness. cough is not only a major distressing and disabling symptom but also an independent predictor of disease progression and death in ipf. recent preliminary data suggest a possible effect of pirfenidone on cough. objective: in this study we want to objectively measure the effect of pirfenidone on cough in patients with ipf that are treated with pirfenidone in daily practice . study design: this is a prospective, observational, international multicenter study. intervention: objective 24-hour cough frequency will be recorded using the leicester cough monitor (lcm), a validated ambulatory cough monitoring system, prior to starting with pirfenidone treatment. the cough recording will be repeated at 4 weeks and at 12 weeks during treatment with pirfenidone. at the days of cough recording, patients will be asked to fill in questionnaires related to cough and to quality of life. patient will be treated according to normal clinical practice at their physician's discretion. main study parameters/endpoints: the primary endpoint is change in cough frequency measured by the leicester cough monitor at week 12 compared to baseline. secondary endpoints look at the relationships between cough, change in cough, quality of life and clinical parameters.

Eligibility criteria:
inclusion criteria: * diagnosis of ipf according to american thoracic society (ats) / european respiratory society (ers) criteria (5), definite and probable patients will be eligible * written informed consent * daily cough related to ipf (exclusion of other causes) present \> 8 weeks * cough score on visual analogue scale of ≥ 40 mm. * carbon monoxide transfer capacity corrected for hemoglobin (tlcoc) ≥ 30% and forced vital capacity (fvc) ≥ 50% * pirfenidone therapy about to be initiated * if a history positive for gastro esophageal reflux (ger), using proton pump inhibitor (ppi) \> 4 weeks exclusion criteria: * opiates, antitussive medication, antihistamines, steroids \> equivalent of 10 mg prednisone or n-acetylcysteine (nac) within two weeks before study * change of steroid \< 10 mg, inhalation steroids within 2 weeks of the study - history of bronchial hyper responsiveness or asthma or relevant airway obstruction (fev1/fvc \< 0.7) * within 6 weeks of the start signs of respiratory tract infection, change of sputum production and fever.

Keywords: idiopathic pulmonary fibrosis cough quality of life
an efficacy study of stain control of a 67% sodium bicarbonate containing toothpaste on chlorhexidine tooth staining

Conditions: Oral Hygiene

Summary: the aim of this study is to compare the stain effect on teeth of twice daily brushing with a 67% sodium bicarbonate containing toothpaste versus standard toothpaste (not containing sodium bicarbonate) for six weeks whilst using a chlorhexidine digluconate 0.2% mouthwash.


Eligibility criteria:
inclusion criteria: * good oral health in the opinion of the investigator (excluding gingivitis) * a minimum of 11 of the 12 permanent gradable anterior teeth at screening * stain levels on the buccal surfaces of the 6 maxillary and 6 mandibular anterior teeth need to be at least "mild" and present on a minimum of 4 teeth * modification of the lobene stain index - at visit 2, a baseline total mlsi intensity x area score (four sites per tooth) of greater than or equal to 8 for facial surfaces of anterior teeth. exclusion criteria: * pregnant women or women who are intending to become pregnant over the duration of the study * known or suspected intolerance or hypersensitivity to chlorhexidine or other study materials (or closely related compounds). * current use of chlorhexidine, cetylpyridinium chloride or any marketed mouthwash * past or current use of any drug which is known to be associated with tooth discolouration within 30 days of screening or during the study period. * recent history (within the last 1 year) of alcohol or other substance abuse * dental conditions / disease requiring immediate treatment; crowns or veneers on more than one anterior tooth; pre-existing sensitivity to oral care products; severe periodontitis; severe recession; dental implants; active carious lesions on anterior teeth; oral lesions/manifestations; prone to aphthous stomatitis and ulceration etc. * participant with untreated oral mucosal disease which in the opinion of the investigator could interfere with the study. * medical condition which would require the use of prophylactic antibiotics prior to dental cleanings * current or relevant history of any serious, severe or unstable physical or psychiatric illness or any medical disorder that would make the participant unlikely to fully complete the study or any condition that presents undue risk from the study treatment or procedures in the opinion of the investigator or dental assessor.
impact of timing of drainage of massive ascites on operative and post-operative course in living-donor liver transplant recipients. a prospective randomized controlled trial.

Conditions: Massive Ascites

Summary: massive ascites is usually controlled over several weeks pre-operatively in liver transplant recipients with the risk of encephalopathy and peritonitis. we hypothesized that intra-operative drainage of ascites will be safe and avoids the inherent risks of pre-operative drainage.


Eligibility criteria:
inclusion criteria: * liver transplant candidates with tense acsites exclusion criteria: * severe coagulpathy (inr more than 2 or platlet count less than 50) meld more than 20
evaluation of the efficacy and safety of qva149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate fdc (50/500 µg b.i.d.) in patients with moderate to severe copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this study will evaluate the efficacy and safety of qva149 (110/50 μg o.d.) vs tiotropium (18 µg o.d.) + salmeterol/fluticasone propionate fdc (50/500 µg b.i.d.) in patients with moderate to severe copd


Eligibility criteria:
inclusion criteria: * patients who have signed informed consent form prior to initiation of any study-related procedure. * male and female adults aged ≥ 40 years. * patients with moderate to severe airflow obstruction with stable copd (stage 2 or stage 3) according to the 2014 gold guidelines. * patients with a post-bronchodilator fev1 ≥40 and \< 80% of the predicted normal value, and post-bronchodilator fev1/fvc \< 0.70 at run-in visit 101. (post refers to 15 min after inhalation of 400 µg of salbutamol). * current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1 pack /day x 10 years, or ½ pack/day x 20 years). an ex-smoker is defined as a patient who has not smoked for ≥ 6 months at screening. * patients who are on triple treatment at least for the last 6 months (lama +laba/ics). exclusion criteria: * patients who have not achieved acceptable spirometry results at visit 101 in accordance with ats (american thoracic society)/ers (european respiratory society) criteria for acceptability (one retest may be performed for patients that don't meet the acceptability criteria) . * patients who have had more than one copd exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the last year prior to visit 1. * patients who developed a copd exacerbation of any severity either 6 weeks before the screening (visit 1) or between screening (visit 1) and treatment (visit 201) will not be eligible but will be permitted to be re-screened after a minimum of 6 weeks after the resolution of the copd exacerbation. other protocol-defined inclusion/exclusion criteria may apply

Keywords: copd, qva149
study of epigallocatechin-3-gallate (egcg) for esophagus protection in patients with lung cancer receiving radial radiotherapy

Conditions: Lung Neoplasms; Esophagitis; Prevention & Control; Epigallocatechin Gallate

Summary: the investigators conducted this phase ii study of egcg therapy protection of the esophagus from damage induced by radiotherapy. in order to observe the effectiveness of egcg, esophageal toxicity was recorded weekly using a grading scale based on symptomatology, following the radiation therapy oncology group (rtog) scoring system. patient-reported pain related to esophagitis was measured using the numerical rating scale (nrs) every week from egcg application to 2 weeks after the end of radiotherapy. the scales are translated into chinese and guides in chinese are developed instructing how to use the scales and perform the assessments.


Eligibility criteria:
inclusion criteria: * pathologically documented lc * considered medically inoperable stage iiia or stage iiib or limited stage small cell lung cancer * age ≥18 years * karnofsky ≥70 * adequate hematologic, hepatic and renal function * fev1 \> 800 cc * mean esophagus dose \>20 gy exclusion criteria were as follows: * a known allergy or hypersensitivity to egcg * pregnancy or lactation * prior radiation to the thorax

Keywords: lung neoplasms esophagitis prevention & control epigallocatechin gallate
investigating participation patterns of patients in atopic dermatitis clinical trials

Conditions: Atopic Dermatitis

Summary: clinical trials, specifically focused on atopic dermatitis, are crucial in assessing the safety and efficacy of new treatments. these trials serve as fundamental instruments in determining whether emerging medications outperform standard therapies, providing compelling evidence to support wider implementation. the main goal is to thoroughly scrutinize trial completion rates and voluntary withdrawals among this particular group of patients.


Eligibility criteria:
inclusion criteria: * ability to understand and the willingness to sign a written informed consent document * participant must be 18 years of age or older * confirmed diagnosis of atopic dermatitis exclusion criteria: * enrolled in another research study * is pregnant, breastfeeding or expecting to conceive within the projected duration of the study * inability to provide written informed consent

Keywords: atopic dermatitis
the clinical efficacy and influence factors of individualized treatment of ustekinumab in crohn's disease

Conditions: IBD (Inflammatory Bowel Disease)

Summary: the loss of response rate of ustekinumab(ust) is high, and the specific mechanism has not yet been elucidated. our study aimed to retrospectively analyze the clinical efficacy and influence factors of individualized treatment of ustekinumab (ust) in patients with crohn's disease (cd).

interleukin (il-12) and interleukin (il-23) co-contain the p40 subunit, and ustekinumab (ust) is a fully humanized igg1 monoclonal antibody that targets the p40 subunit. the conventional regimen of ust in the treatment of crohn's disease is that after the first sufficient dose (6 mg/kg) of intravenous infusion, 90 mg ust is injected subcutaneously at the 8th week according to the patient's response, and maintenance therapy is given every 8 or 12 weeks. however, data from real-world studies suggest that the clinical efficacy of treating cd with the conventional ust regimen is less than ideal.our study aimed to retrospectively analyze the clinical efficacy and influence factors of individualized treatment of ustekinumab in patients with crohn's disease .

Eligibility criteria:
inclusion criteria: 1. diagnosed with moderate to severe crohn's disease 2. receiving treatment with ustekinumab exclusion criteria: 1. combined with other autoimmune diseases (such as systemic lupus erythematosus, sjogren's syndrome, etc.), malignant tumors, or severe cardiovascular and cerebrovascular diseases 2. merge active tuberculosis or severe infection 3. liver and kidney dysfunction 4. pregnancy or lactation period 5. combination therapy with hormones, immunosuppressants, small molecule drugs, or other biological agents 6. clinical data missing ≥ 30% or lost to follow-up during the follow-up period.

Keywords: ustekinumab individualized treatment clinical efficacy crohn&#39;s disease